We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen reported a net income of $2.95 billion on revenue of $14.27 billion in 2006, compared with a net income of $3.67 billion on revenue of $12.43 billion in 2005.
Wyeth affirmed its strong financial forecast for 2007, although the company faces challenges from a prolonged FDA facility inspection, new generic competitors and litigation over its hormone-replacement therapies.
Technology holds the key to improving drug development through product life cycle management (PLM), which allows for greater collaboration in the development, sale and service of products, industry experts say.
The market for biomaterials is expanding as medical device manufacturers seek to integrate lighter, safer, sturdier materials into implantable products such as drug-eluting stents, an analyst said in a recent briefing.
Healthcare spending will continue to grow more quickly than the economy over the next decade as more Americans join government-provided healthcare programs, according to a report from economists at the Centers for Medicare & Medicaid Services (CMS).
Market growth in the orthopedic device sector should expand significantly over 2007 and 2008, an analyst said in a summary of the recent American Academy of Orthopaedic Surgeons meeting.
The market for biomaterials is expanding as medical device manufacturers seek to integrate lighter, safer, sturdier materials into implantable products such as drug-eluting stents, an analyst said in a recent briefing.
Healthcare spending will continue to grow more quickly than the economy over the next decade as more Americans join government-provided healthcare programs, according to a report from economists at the Centers for Medicare & Medicaid Services.
Roche’s and Genentech’s stocks took a hit after the companies announced lower doses of their drug Avastin were as effective in treating lung cancer as higher doses.
Merck has decided to pull back its lobbying efforts to promote state-mandated vaccinations of adolescent girls with Gardasil, a vaccine to guard against two strains of the human papillomavirus (HPV), a company representative confirmed.